OOIR: Observatory of International Research

Papers

(The H4-Index of npj Parkinsons Disease is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	301
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	176
Subthalamic nucleus in patients with Parkinson’s disease encodes changes and magnitude of applied force	143
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	129
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network	128
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	124
Biological aging predicts mortality in Parkinson’s patients: evidence from UK Biobank	118
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	113
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	108
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	107
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	103
Physiotherapy interventions for balance impairments in Parkinson’s disease: evidence from a systematic review and dose-response meta-analysis	94
Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson’s disease	94
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	92
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	86
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	85
Differences in brain aging between sexes in Parkinson’s disease	84
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	83
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	83
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	81
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	80
Video-based machine learning models for predicting deep brain stimulation outcomes in Parkinson’s disease patients	79
Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease	78
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	76
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	72

Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	71
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	71
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide	71
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	70
The pattern of fMRI activation with STN DBS reveals symptom-specific networks	69
The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model	65
The IC-SNc neural circuit mediates prepulse inhibition deficits in MPTP-induced Parkinson’s disease male mice	65
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	63
Advanced brain aging in Parkinson’s disease with cognitive impairment	61
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	60
The experience of Anxiety for people with Parkinson’s disease	60
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	59
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	59
Machine learning prediction of discharge destination in patients with Parkinson’s disease; a nationwide cohort study	58
Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments	58
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	57
Elevated levels of colonic interleukin-1beta and interleukin-8 in isolated REM sleep behavior disorder without associated changes in permeability	55
JNK3 quantification in plasma: a novel biomarker for neuronal damage in Parkinson’s disease	55
Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease	55
Optimizing the MDS-UPDRS Part III for early-stage Parkinson’s: early supportive evidence for a limb-related bradykinesia/rigidity sub-score	54
In memorium, Michael Zigmond, PhD	54
Single-cell analysis of the peripheral immune landscape in Parkinson’s disease: insights into dendritic cell and CD4+ T-cell transcriptomics	54
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	54
Resting and action tremor in Parkinson’s disease: pathophysiological insights from long-term STN-DBS	53
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	51
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease	50
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	50
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis	50